By Kathryn Lurie DAVOS, Switzerland (Reuters) - Climate change came to the fore at the World Economic Forum's annual meeting, where U.N. Secretary-General Antonio Guterres called...
By Sinéad Carew and Shreyashi Sanyal (Reuters) - The S&P 500 and the Dow lost almost 2% on Wednesday, their biggest daily drops in more than a month, after weak economic data...
DAVOS, Switzerland (Reuters) - Moderna (NASDAQ:MRNA) chief executive Stephane Bancel said he would like to have factories making vaccines based on its messenger RNA technology...
The week before Christmas tends to be relatively quiet regarding economic announcements, but volatility remains high, and markets are still digesting last week’s data. The global...
Robust pipeline of over 90 drugs, vaccinations make up 38% of revenues Reported its highest quarterly sales in history in Q2 2022 Recession-resistant due to COVID-19 vaccine...
NVAX stock is down 16% this week, bringing its 12-month loss to over 88%. The company is struggling to meet revenue expectations from its Covid-19 vaccine candidate. Demand for...
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.
| Average | 227.88 (+15.66% Upside) |
| High | 506.00 |
| Low | 111.00 |
| Price | 197.02 |
| No. of Analysts | 19 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Neutral | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Sell | Neutral | Buy | Strong Buy | Buy |
| Summary | Strong Sell | Neutral | Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 235.81 | 242.38 | 235.52 | -4.54 | -1.89% | 29.47M | NASDAQ | |||
| 28.81 | 29.82 | 28.63 | -0.79 | -2.67% | 43.01M | NASDAQ | |||
| 53.45 | 57.61 | 53.13 | -1.41 | -2.57% | 8.37M | NYSE | |||
| 12.41 | 12.85 | 12.40 | -0.26 | -2.05% | 48.50M | NYSE | |||
| 53.70 | 54.00 | 53.70 | 0.00 | 0.00% | 0.00 | NYSE | |||
| 135.19 | 138.61 | 135.03 | -0.75 | -0.55% | 68.70M | NASDAQ | |||
| 128.78 | 136.68 | 127.01 | -2.71 | -2.06% | 194.22M | NASDAQ | |||
| 652.29 | 676.11 | 651.54 | -5.90 | -0.90% | 1.15M | NASDAQ | |||
| 45.98 | 47.40 | 45.96 | -0.79 | -1.69% | 3.42M | NASDAQ | |||
| 326.33 | 330.08 | 321.25 | +0.11 | +0.03% | 7.76M | NASDAQ | |||
| 46.90 | 48.27 | 46.89 | -1.18 | -2.45% | 19.85M | NASDAQ | |||
| 177.23 | 182.38 | 176.94 | -3.26 | -1.81% | 8.89M | NYSE | |||
| 233.97 | 239.85 | 233.70 | -2.73 | -1.15% | 349.54K | NYSE | |||
| 113.22 | 116.75 | 113.04 | -1.97 | -1.71% | 15.29M | NYSE | |||
| 91.12 | 92.80 | 90.64 | -0.17 | -0.19% | 28.77M | NASDAQ |